Biogen Backs Out Of Hemophilia, But Who Benefits?
With no buyers in the hemophilia space and a need to create a more streamlined company, Biogen Inc. announced May 3 that it has done the only thing it can – spin out its hemophilia business. It's still unclear whether this will be a positive strategy for either company.
You may also be interested in...
Biopharma financing decreased by 16% in Q2 to $4.8 billion, while the total value of acquisitions nearly doubled to $22 billion, including AbbVie's $9.8 billion takeover of Stemcentrx. Alliances garnered an aggregate potential deal value of $23.1 billion, led by Allergan's CNS agreement with Heptares.
A review of biopharma start-up dealmaking and financing from April through June 2016, based on data from Strategic Transactions.
Bioverativ was unveiled as the name for Biogen’s spin out; an initial Form 10 registration will be filed with SEC later this week.